Boyd Watterson Asset Management LLC OH purchased a new stake in Novartis AG (NYSE:NVS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 2,441 shares of the company’s stock, valued at approximately $204,000.

Several other institutional investors have also bought and sold shares of NVS. Westwood Holdings Group Inc. increased its position in Novartis AG by 5.6% in the first quarter. Westwood Holdings Group Inc. now owns 5,405 shares of the company’s stock valued at $401,000 after buying an additional 285 shares during the period. AT Bancorp increased its position in Novartis AG by 4.2% in the first quarter. AT Bancorp now owns 11,690 shares of the company’s stock valued at $868,000 after buying an additional 470 shares during the period. Physicians Financial Services Inc. increased its position in Novartis AG by 11.4% in the first quarter. Physicians Financial Services Inc. now owns 16,583 shares of the company’s stock valued at $1,232,000 after buying an additional 1,700 shares during the period. Prentiss Smith & Co. Inc. increased its position in Novartis AG by 2.4% in the first quarter. Prentiss Smith & Co. Inc. now owns 136,441 shares of the company’s stock valued at $10,133,000 after buying an additional 3,239 shares during the period. Finally, Mawer Investment Management Ltd. increased its position in Novartis AG by 2.9% in the first quarter. Mawer Investment Management Ltd. now owns 3,122,065 shares of the company’s stock valued at $231,876,000 after buying an additional 88,610 shares during the period. Institutional investors and hedge funds own 11.27% of the company’s stock.

Shares of Novartis AG (NVS) traded down 0.75% during midday trading on Thursday, reaching $83.55. 566,597 shares of the company were exchanged. The company has a market capitalization of $195.75 billion, a PE ratio of 30.50 and a beta of 0.73. The stock’s 50-day moving average price is $84.23 and its 200-day moving average price is $78.55. Novartis AG has a 52-week low of $66.93 and a 52-week high of $86.90.

Novartis AG (NYSE:NVS) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.06. The company had revenue of $12.24 billion during the quarter, compared to analyst estimates of $12.20 billion. Novartis AG had a net margin of 13.52% and a return on equity of 15.51%. The firm’s revenue for the quarter was down 1.8% compared to the same quarter last year. During the same period last year, the business earned $1.23 EPS. Analysts anticipate that Novartis AG will post $4.73 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/boyd-watterson-asset-management-llc-oh-invests-204000-in-novartis-ag-nysenvs/1471148.html.

A number of equities analysts recently commented on the stock. Zacks Investment Research downgraded shares of Novartis AG from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research note on Thursday, June 8th. Morgan Stanley upgraded shares of Novartis AG from an “underweight” rating to an “overweight” rating in a research note on Wednesday, July 26th. Cowen and Company set a $77.00 target price on shares of Novartis AG and gave the stock a “hold” rating in a research note on Tuesday, July 11th. Finally, TheStreet upgraded shares of Novartis AG from a “c+” rating to a “b” rating in a research note on Friday, June 2nd. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and six have given a buy rating to the company’s stock. Novartis AG has an average rating of “Hold” and an average target price of $83.56.

In related news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of the firm’s stock in a transaction on Wednesday, July 5th. The stock was bought at an average cost of $15.00 per share, with a total value of $4,000,005.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 0.01% of the stock is owned by company insiders.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.